Drug Trial Radar · NCT07223216
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Oct 23, 2025
Primary completion
Aug 12, 2026
Study completion Aug 26, 2026
Sponsor
- Lead sponsor
- Biomea Fusion Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese Participants.
Conditions
- Obesity
Interventions
BMF-650Drug
Interventional Product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess safety and tolerability of BMF-650Time frame: 6 weeks (Part 1) 4 and 11 weeks (Part 2 MAD Cohorts 1-4) and 6 weeks (Part 2 MAD Cohort 5)
- Assess safety and tolerability of BMF-650Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
- Assess safety and tolerability of BMF-650Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
- Assess safety and tolerability of BMF-650Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
- Assess safety and tolerability of BMF-650Time frame: 2 weeks (Part 1), 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medpace Clinical Pharmacology
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.